Health
MS patients receiving aCD20 treatment mount robust T-cell responses to COVID-19 vaccines – News-Medical.Net
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells…
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted…
Continue Reading
-
Noosa News21 hours agoIncrease in extreme weather events poses ‘substantial risk’ to blood supplies, researchers warn
-
Noosa News11 hours agoAustralians tell ABC’s Your Say how they saw the second leaders debate
-
General7 hours agoNT Coalition candidate Lisa Siebert diverges from Jacinta Nampijinpa Price on royal commission call
-
Noosa News16 hours agoManjimup engineer turns previously wasted avocados into liquid gold